Learn More:
Learn more:
CLINICAL TRIALS
At Synlogic, we are working to develop potential biotherapeutics based on synthetic biology to treat disease in new ways. We know patients are waiting for new treatment options and we are working tirelessly to make a difference.
Clinical trials are a critical way to study new drugs and advance research. They are a required step to bring any potential new therapy to those in need. Patient community participation in clinical trials can improve the clinical trial process in many ways. Patients help to advance understanding of disease and could affect how patients are treated for generations to come. Without patient involvement, new drugs cannot be approved.
We know that participating in a clinical trial is not always easy. We are grateful to the participants in our programs and in clinical trials around the world. They are true partners in science and innovation as we work together to create potential new treatment options.
Interested in receiving updates on Synlogic’s clinical trails?
Sign-up to stay connected.
Phenylketonuria (PKU) Clinical Trial Program
People living with PKU are not able to break down the amino acid phenylalanine (Phe) found in the natural protein in many foods, including all meat and dairy, as well as breads and cereals. The buildup of Phe can be neurotoxic, meaning dangerous for the brain. Synlogic has developed a potential therapy for PKU that has been designed to break down Phe. The potential therapy is a specially engineered probiotic that is taken orally (as a powder, mixed with a liquid like water). Synlogic has a clinical trial program, called Synpheny, to evaluate labafenogene marselecobac (previously known as SYNB1934), this potential therapy.
To receive updates about our PKU program, including our pivotal Phase 3 trial, Synpheny-3, sign-up to stay connected. You can also learn more about Synpheny-3 at www.pkuresearchstudy.com.
Homocystinuria (HCU) Clinical Trial Program
SYNB1353, a potential treatment for HCU, is a genetically engineered probiotic designed to consume methionine, a precursor to homocysteine, in the GI tract. The goal of treatment in HCU is to lower and control levels of total homocysteine (tHcy). SYNB1353 has achieved proof of mechanism in a Phase 1 study using a dietary model of homocystinuria in healthy volunteers.
To receive updates about our HCU program, please email: patients@synlogictx.com
For Physicians
For more information on any Synlogic-sponsored clinical trials, please contact our clinical operations team at contact-us@synlogictx.com.